Loading
Idarubicin is an anthracycline chemotherapy approved in 1990 for adult acute myeloid leukaemia, given with cytarabine in 3+7 induction and FLAG-Ida salvage and in acute promyelocytic leukaemia protocols. Randomised trials showed more complete remissions than with daunorubicin, which is why centres prefer it; heart damage, marrow suppression and extravasation injury are the class risks.
Idarubicin was approved in 1990 for adult acute myeloid leukaemia as part of combination induction. Four randomised trials totalling 823 newly diagnosed patients (Memorial Sloan Kettering, Southeastern Cancer Study Group, US multicentre and GIMEMA) compared idarubicin with daunorubicin, each with cytarabine, and showed higher complete remission rates and, in some, longer survival with idarubicin; it is a standard induction anthracycline (for example in the 3+7 and the FLAG-Ida salvage regimens) and in acute promyelocytic leukaemia protocols with all-trans retinoic acid. Cardiotoxicity, severe myelosuppression and extravasation injury are the class risks.
4-demethoxy analogue of daunorubicin; more lipophilic, with an active metabolite (idarubicinol); intercalates DNA and inhibits topoisomerase II.
1.Idarubicin slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 1990 | Adult acute myeloid leukaemia, as a component of combination induction chemotherapy |
Read for the class this product belongs to (anthracyclines) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Idarubicin" OR ABSTRACT:"Idarubicin" OR TITLE:"Idamycin PFS" OR ABSTRACT:"Idamycin PFS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Idarubicin, not a curated reading list.
Shares ALL R3: mitoxantrone versus idarubicin in first relapse of childhood acute lymphoblastic leukaemia, Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia, A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML, ALL R3 (UKALLR3) and the tag generic.
Shares Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia, Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag generic.
Shares Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia, Cytotoxic chemotherapy and the tag generic.
Shares Pfizer (incl. Seagen), Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML, Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.